Mucosal Immune Response and Immune Tolerance of Recombinant Lactococcus lactis in Mice by Intranasal Immunization
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
The food-grade Nisin controlled expression (NICE) system of Lactococcus lactis (L.lacti) was studied emphatically as a vector of recombinant protein expression. The therapeutic proteins or protective antigen protein expressed can secrete and anchor in the cell envelope or bacterial peptidoglycans and thus the NICE system of L.lacti can present the vaccine antigen to the mucosal surface and result in a specific s-IgA response. Using recombinant L.lacti that present antigens as live mucosal vaccines provides an effective way to prevent microorganisms invading and shows a promising future. In this study, BALB/c mice were immunized with the bacterial supernatant to evaluate the mucosal immune response and Immune tolerance of recombinant L.1acti PNZ8149/NZ3900-M/PRRS strain that expresses ORF6 gene of PRRSV,. IgG in serum and s-IgA in lung lavage fluid and intestinal washes were analyzed by using a similar enzyme-linked immunosorbent assay (ELISA). For evaluating changes in cytokines IL-4 and IL-10, the spleen collected was analyzed. The results clearly showed that mice immunized with recombinant strain PNZ8149/NZ3900-M/PRRS could induce remarkable special s-IgA in lung lavage fluid, at the whole experimental session, compared with the control group I and II. The level of special s-IgA and IgG showed significantly increase(P<0.01) and IL-4 and IL-10 contents of cytokines showed little difference to those of the control groups. All the results indicated that mice immunized by the recombinant L.lactis expressing ORF6 gene of PRRSV can significantly induce mucosal immune responses and avoid producing the phenomenon of mucosal immune tolerance.The study was expected to lay a theoretical foundation on developing of the gene engineering L.1acti s mucosal vaccines.
